NEURONAL DEFENSE
Live / Allowed — Notice of allowance issued (as of 18 Aug 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 24 Sept 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99409682
- Mark type
- Word mark
- Filed
- 24 Sept 2025
- Published for opposition
- 23 Jun 2026
- Attorney of record
- Monte L. Falcoff
Goods and services
- Class 005 — Pharmaceuticals: Natural dietary supplements comprising nanomicellar veterinary formulations of phenylpropyl silanetriol (PTS) carriers in combination with bioactive compounds for use in companion animals for supporting cognitive function, memory, learning ability and neural health in aging animals, mitigating oxidative stress and neuroinflammation associated with neurodegenerative processes, protecting and promoting survival of dopaminergic neurons in toxin-induced models of Parkinson-type and other neurodegenerations, providing prophylactic and therapeutic neuroprotection against environmental and endogenous neurotoxins, supporting nerve regeneration and repair following trauma, surgery or peripheral neuropathy, alleviating chemotherapy-induced neurotoxicity, including cisplatin-related peripheral neuropathy, supporting motor coordination, balance and reduction of gait abnormalities, modulating systemic inflammatory responses and supporting central cardiovascular regulatory mechanisms in endotoxemia and SIRS models, maintaining cardiovascular health through antioxidant and anti-inflammatory actions, promoting ocular health by protecting retinal neurons from oxidative damage, providing adaptogenic support to reduce stress, anxiety and behavioral disorders, and supporting gut-brain axis homeostasis to indirectly influence mood and neural function; Pharmaceutical preparations comprising nanomicellar veterinary formulations of phenylpropyl silanetriol (PTS) carriers in combination with bioactive compounds for use in companion animals for supporting cognitive function, memory, learning ability and neural health in aging animals, mitigating oxidative stress and neuroinflammation associated with neurodegenerative processes, protecting and promoting survival of dopaminergic neurons in toxin-induced models of Parkinson-type and other neurodegenerations, providing prophylactic and therapeutic neuroprotection against environmental and endogenous neurotoxins, supporting nerve regeneration ; and repair following trauma, surgery or peripheral neuropathy, alleviating chemotherapy-induced neurotoxicity, including cisplatin-related peripheral neuropathy, supporting motor coordination, balance and reduction of gait abnormalities, modulating systemic inflammatory responses and supporting central cardiovascular regulatory mechanisms in endotoxemia and SIRS models, maintaining cardiovascular health through antioxidant and anti-inflammatory actions, promoting ocular health by protecting retinal neurons from oxidative damage, providing adaptogenic support to reduce stress, anxiety and behavioral disorders, and supporting gut-brain axis homeostasis to indirectly influence mood and neural function.
Owner
- SoluPet Inc., Toronto, CA
- SoluPet Inc., Toronto, CA
Prosecution history
- 18 Aug 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 23 Jun 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 23 Jun 2026 — PUBLISHED FOR OPPOSITION
- 17 Jun 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 26 May 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 16 May 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 16 May 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 16 May 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 19 Feb 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 19 Feb 2026 — NON-FINAL ACTION E-MAILED
- 19 Feb 2026 — NON-FINAL ACTION WRITTEN
- 30 Jan 2026 — ASSIGNED TO EXAMINER
- 16 Nov 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 16 Nov 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 16 Nov 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED